GlassScriptPhysician profile
Megan E Mcgarvey
NPI 1255563565
$1,779.43
in general payments reported to CMS, 2019-2025
23 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $27.19 · 2021: $274 · 2022: $395 · 2023: $159 · 2024: $316 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.67 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $216.48 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $180.19 | 2020-2025 | Farxiga |
| Novo Nordisk INC | $172.47 | 2021-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $161.70 | 2019-2025 | |
| Beta Bionics, INC. | $102.66 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $95.16 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $86.97 | 2019-2025 | Mounjaro, Zepbound |
| Insulet Corporation | $80.54 | 2019 | |
| Horizon Therapeutics Plc | $60.22 | 2021-2022 | |
| Becton, Dickinson and Company | $54.44 | 2021 | |
| Medtronic, INC. | $53.37 | 2022-2024 | Intellis Adaptivestim |
| Alexion Pharmaceuticals, INC. | $37.65 | 2019 | |
| Dexcom, INC. | $27.68 | 2019 | |
| Ascensia Diabetes Care US INC. | $26.41 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.14 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.24 | 2019 | |
| Tandem Diabetes Care, INC. | $19.13 | 2022 | |
| Antares Pharma, INC. | $17.82 | 2019 | |
| Viiv Healthcare Company | $17.81 | 2024 | Cabenuva |
| Medtronic Minimed, INC. | $17.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.75 | 2019 | |
| Mannkind Corporation | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Mcgarvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.